These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37379361)

  • 61. Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors.
    Çuburu N; Bialkowski L; Pontejo SM; Sethi SK; Bell ATF; Kim R; Thompson CD; Lowy DR; Schiller JT
    Proc Natl Acad Sci U S A; 2022 Jun; 119(26):e2116738119. PubMed ID: 35749366
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens.
    Miller AM; Bahmanof M; Zehn D; Cohen EEW; Schoenberger SP
    Cancer Immunol Res; 2019 Jan; 7(1):40-49. PubMed ID: 30482746
    [TBL] [Abstract][Full Text] [Related]  

  • 63. T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3.
    Quatromoni JG; Morris LF; Donahue TR; Wang Y; McBride W; Chatila T; Economou JS
    J Hematol Oncol; 2011 Nov; 4():48. PubMed ID: 22112546
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection.
    Schreurs MW; de Boer AJ; Figdor CG; Adema GJ
    Cancer Res; 1998 Jun; 58(12):2509-14. PubMed ID: 9635569
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hydrodynamic limb vein delivery of a xenogeneic DNA cancer vaccine effectively induces antitumor immunity.
    Neal ZC; Bates MK; Albertini MR; Herweijer H
    Mol Ther; 2007 Feb; 15(2):422-30. PubMed ID: 17235322
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Intratumoral injection of interferon-gamma gene-modified dendritic cells elicits potent antitumor effects: effective induction of tumor-specific CD8+ CTL response.
    Pan J; Zhang M; Wang J; Wang Q; Xia D; Sun W; Zhang L; Yu H; Cao X
    J Cancer Res Clin Oncol; 2005 Jul; 131(7):468-78. PubMed ID: 15711825
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1.
    Quixabeira DCA; Cervera-Carrascon V; Santos JM; Clubb JHA; Kudling TV; Basnet S; Heiniö C; Grönberg-Vähä-Koskela S; Anttila M; Havunen R; Kanerva A; Hemminki A
    Oncoimmunology; 2022; 11(1):2028960. PubMed ID: 35083096
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Multifunctional nanoparticles precisely reprogram the tumor microenvironment and potentiate antitumor immunotherapy after near-infrared-II light-mediated photothermal therapy.
    Ge Y; Zhang J; Jin K; Ye Z; Wang W; Zhou Z; Ye J
    Acta Biomater; 2023 Sep; 167():551-563. PubMed ID: 37302731
    [TBL] [Abstract][Full Text] [Related]  

  • 69. In vivo delivery of antigens by adenovirus dodecahedron induces cellular and humoral immune responses to elicit antitumor immunity.
    Villegas-Mendez A; Garin MI; Pineda-Molina E; Veratti E; Bueren JA; Fender P; Lenormand JL
    Mol Ther; 2010 May; 18(5):1046-53. PubMed ID: 20179681
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The induction of antigen-specific CTL by in situ Ad-REIC gene therapy.
    Ariyoshi Y; Watanabe M; Eikawa S; Yamazaki C; Sadahira T; Hirata T; Araki M; Ebara S; Nasu Y; Udono H; Kumon H
    Gene Ther; 2016 May; 23(5):408-14. PubMed ID: 26836118
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
    Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
    Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
    [TBL] [Abstract][Full Text] [Related]  

  • 72. CD4(+) T cell-released exosomes inhibit CD8(+) cytotoxic T-lymphocyte responses and antitumor immunity.
    Zhang H; Xie Y; Li W; Chibbar R; Xiong S; Xiang J
    Cell Mol Immunol; 2011 Jan; 8(1):23-30. PubMed ID: 21200381
    [TBL] [Abstract][Full Text] [Related]  

  • 73. PolySia-Specific Retargeting of Oncolytic Viruses Triggers Tumor-Specific Immune Responses and Facilitates Therapy of Disseminated Lung Cancer.
    Kloos A; Woller N; Gürlevik E; Ureche CI; Niemann J; Armbrecht N; Martin NT; Geffers R; Manns MP; Gerardy-Schahn R; Kühnel F
    Cancer Immunol Res; 2015 Jul; 3(7):751-63. PubMed ID: 25701327
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy.
    Oh E; Oh JE; Hong J; Chung Y; Lee Y; Park KD; Kim S; Yun CO
    J Control Release; 2017 Aug; 259():115-127. PubMed ID: 28336378
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity.
    Guo G; Yu M; Xiao W; Celis E; Cui Y
    Cancer Res; 2017 May; 77(9):2292-2305. PubMed ID: 28280037
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity.
    Yang J; Yan C; Vilgelm AE; Chen SC; Ayers GD; Johnson CA; Richmond A
    Cancer Immunol Res; 2021 Feb; 9(2):200-213. PubMed ID: 33177110
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site.
    Lopes A; Feola S; Ligot S; Fusciello M; Vandermeulen G; Préat V; Cerullo V
    J Immunother Cancer; 2019 Jul; 7(1):174. PubMed ID: 31291991
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer.
    Marelli G; Chard Dunmall LS; Yuan M; Di Gioia C; Miao J; Cheng Z; Zhang Z; Liu P; Ahmed J; Gangeswaran R; Lemoine N; Wang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500259
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors.
    Aranda F; Llopiz D; Díaz-Valdés N; Riezu-Boj JI; Bezunartea J; Ruiz M; Martínez M; Durantez M; Mansilla C; Prieto J; Lasarte JJ; Borrás-Cuesta F; Sarobe P
    Cancer Res; 2011 May; 71(9):3214-24. PubMed ID: 21402711
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice.
    Chinnasamy D; Tran E; Yu Z; Morgan RA; Restifo NP; Rosenberg SA
    Cancer Res; 2013 Jun; 73(11):3371-80. PubMed ID: 23633494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.